Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.01007-19. doi: 10.1128/AAC.01007-19. [Epub ahead of print]

A multicenter study of the real-world use of ceftaroline versus vancomycin for acute bacterial skin and skin structure infections.

Author information

1
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
2
Medication Outcomes Center, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA.
3
Department of Clinical Sciences, College of Pharmacy, Touro University California, Vallejo, CA.
4
Department of Pharmacy Practice, School of Pharmacy, University of Maryland, Baltimore, MD.
5
Department of Pharmacy, Lee Health, Fort Myers, FL.
6
T2 Biosystems Inc, Lexington, MA.
7
Infectious Diseases Division, Mon Health, Morgantown, WV.
8
Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, Glendale, AZ.
9
College of Pharmacy, University of Florida, Gainesville, FL.
10
Merck & Co., Inc, Kenilworth, NJ. At the time of this study he was employed by the College of Pharmacy, University of Florida, Gainesville, FL.
11
Division of Infectious Diseases, University of Michigan, Ann Arbor, MI.
12
Department of Pharmacy, Henry Ford Hospital, Detroit, MI.
13
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA m.rybak@wayne.edu.
14
Department of Medicine, Wayne State University, Detroit, MI.
15
Department of Pharmacy, Detroit Medical Center, Detroit, MI.

Abstract

Objective: To determine if real-world ceftaroline treatment in adults hospitalized for acute bacterial skin and skin structure infections (ABSSSI) is associated with decreased infection-related length of stay (LOSInf ) compared to vancomycin.Design: Retrospective, multicenter, cohort study from 2012 to 2017. Cox proportional hazard regression, propensity score matching and inverse probability of treatment weighting (IPTW) were used to determine the independent effect of treatment group on LOSInf. Setting: Four academic medical centers and two community hospitals in Arizona, Florida, Michigan, and West Virginia, United States.Patients: Adults hospitalized with ABSSSI and treated with ceftaroline or vancomycin for ≥72 hours within 120 hours of diagnosis.Results: A total of 724 patients were included (325 ceftaroline and 399 vancomycin). In general, ceftaroline patients had characteristics consistent with a higher risk of poor outcomes. The unadjusted median LOSinf was 5 (3, 7) days and 6 (4, 8) days in the vancomycin and ceftaroline group, respectively (HR, 0.866, 95% CI 0.747, 1.002). The Cox proportional hazard model, propensity score matched and IPTW analyses demonstrated no significant difference in LOSInf between groups (aHR, 0.891; 95% CI 0.748, 1.060; aHR 0.955, 95% CI 0.786, 1.159; aHR 0.918, 95% CI 0.793, 1.063, respectively). Patients treated with ceftaroline were significantly more likely to meet criteria for discharge readiness at day three in unadjusted and adjusted analyses.Conclusions: Although discharge readiness at day three was higher in ceftaroline treated patients, LOSInf was similar between treatment groups. Clinical and non-clinical factors were associated with LOSInf.

PMID:
31405859
DOI:
10.1128/AAC.01007-19

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center